The Centers for Disease Control and Prevention yesterday issued a health advisory warning of an uptick over the last year in meningococcal disease in which isolates show the gene associated with penicillin resistance and mutations associated with ciprofloxacin resistance.

CDC said the majority of cases were in Hispanic individuals.

The agency recommends the following for providers and clinicians:

  • Health care providers should perform antimicrobial susceptibility testing to determine susceptibility of all meningococcal isolates to penicillin before changing from empirical treatment with cefotaxime or ceftriaxone to penicillin or ampicillin.
  • In states that have experienced meningococcal disease cases caused by ciprofloxacin-resistant strains within the past 1–2 years, clinicians and public health staff should consider AST on meningococcal isolates to inform prophylaxis decisions. AST should not delay the initiation of prophylaxis with ciprofloxacin, rifampin or ceftriaxone.

Related News Articles

Headline
As part of Community Health Improvement Week June 9-13, two experts from Corewell Health share how an impactful health care ecosystem model is supporting local…
Headline
With June 9-13 being Community Health Improvement Week, three experts from HonorHealth discuss how the health care network is addressing community needs beyond…
Headline
A new AHA video highlights how Corewell Health is transforming youth behavioral health care access in rural Michigan through school-based clinics and…
Headline
The Food and Drug Administration May 16 announced it cleared the first blood test to diagnose Alzheimer’s disease. The test, created by Fujirebio Diagnostics,…
Headline
Zaira Khalid, M.D., senior staff geriatric psychiatrist at Henry Ford Behavioral Health Hospital, discusses the unique physical, emotional and social needs of…
Headline
An estimated 7.2 million Americans are living with Alzheimer's disease, according to the latest annual report by the Alzheimer's Association. Nearly two-thirds…